EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer

Azka Ali iD, William E Barlow iD, Halle C F Moore iD, Timothy J Hobday, Claudine Isaacs iD, Muhammad Salim, Kathy S Albain iD, Helen K Chew iD, Gary V Burton, Gordan Srkalovic iD, Bradley A McGregor iD, Lawrence E Flaherty iD und 6 weitere

JNCI Cancer Spectrum · 03.03.2026 · 10 (2)

DOI: 10.1093/jncics/pkag024 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 15.03.2026. Verfasst von Azka Ali und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Breast Neoplasms, Male. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI grants, NCI NIH HHS, Amgen, Inc. Clinical trial information.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

S0221 investigated weekly vs every 2 weeks dosing of doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel in patients with high-risk early breast cancer. After an interim analysis, random assignment to the 2 AC arms was stopped for futility, and the trial was modified to study only the paclitaxel schedules.

Methods

Between December 2003 and November 2010, a total of 2716 patients were randomly assigned in a 2 × 2 factorial design to 15 weeks of weekly A and daily C vs 6 cycles of every 2 weeks AC; and weekly paclitaxel for 12 weeks vs 6 cycles of every 2 weeks paclitaxel. Between January 2011 and January 2012, an additional 578 patients were assigned to 4 cycles of every 2 weeks AC and randomly assigned to weekly vs every 2 weeks paclitaxel. Updated survival was assessed using log-rank tests and Cox regression models. We compared outcomes by breast cancer subtype as well.

Results

At a median follow-up of 12.1 years, there were no statistically significant differences among the 4 treatment arms in disease-free survival (DFS) (P = .91) or overall survival (P = .34) in the original protocol. Among the 578 patients assigned AC for 4 cycles and randomly assigned to paclitaxel weekly vs every 2 weeks paclitaxel, there were no overall differences in DFS (P = .32) or overall survival (P = .42).

Conclusion

As there were no statistically significant outcome differences in DFS or overall survival between the studied schedules of AC and paclitaxel with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBreast Neoplasms, MaleAdultAgedFemaleHumansMaleMiddle AgedCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFollow-Up StudiesPaclitaxelProportional Hazards ModelsTaxoidsTime FactorsYoung AdultAged, 80 and over

Substanzen

CyclophosphamideDoxorubicinPaclitaxelTaxoids

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH, United States.
  • Department of Biostatistics, University of Washigton, SWOG Statistics and Data Management Center, Seattle, WA, United States.
  • Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, United States.
  • Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, United States.
  • Division of Oncology, Allan Blair Cancer Center, Regina, Saskatchewan, Canada.
  • Division of Hematology and Oncology, Loyola University Chicago, Stritch School of Medicine, Chicago, IL, United States.

ORCID-Profile: Azka Ali, William E Barlow, Halle C F Moore, Claudine Isaacs, Kathy S Albain, Helen K Chew, Gordan Srkalovic, Bradley A McGregor, Lawrence E Flaherty, Julie R Gralow, Priyanka Sharma, Lajos Pusztai, George T Budd

Förderung

  • NCI grants
  • NCI NIH HHS
  • Amgen, Inc. Clinical trial information

Zitieren

APA

Ali, A., Barlow, W. E., Moore, H. C. F., Hobday, T. J., Isaacs, C., Salim, M., Albain, K. S., Chew, H. K., Burton, G. V., Srkalovic, G., McGregor, B. A., Flaherty, L. E., Lew, D. L., Gralow, J. R., Hortobagyi, G. N., Sharma, P., Pusztai, L., & Budd, G. T. (2026). Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. JNCI Cancer Spectrum, 10(2). https://doi.org/10.1093/jncics/pkag024

Vancouver

Ali A, Barlow WE, Moore HCF, Hobday TJ, Isaacs C, Salim M, et al. Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. JNCI Cancer Spectrum. 2026;10(2). doi:10.1093/jncics/pkag024

BibTeX
@article{Ali2026,
  author = {Ali, Azka and Barlow, William E and Moore, Halle C F and Hobday, Timothy J and Isaacs, Claudine and Salim, Muhammad and Albain, Kathy S and Chew, Helen K and Burton, Gary V and Srkalovic, Gordan and McGregor, Bradley A and Flaherty, Lawrence E and Lew, Danika L and Gralow, Julie R and Hortobagyi, Gabriel N and Sharma, Priyanka and Pusztai, Lajos and Budd, George T},
  title = {Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.1093/jncics/pkag024}
}
Kostenlos starten →